Administer by oral inhalation using a suitable nebulizer until the nebulizer chamber is empty. Do not swallow the solution. The full duration of nebulization takes approximately 5-15 minutes.

Salbutamol selectively stimulates beta-2 adrenergic receptors in bronchial smooth muscle, leading to bronchodilation. Ipratropium Bromide is an anticholinergic agent that blocks muscarinic receptors in the airways, preventing bronchoconstriction and causing bronchodilation. The combination provides an additive effect.

• •Hypersensitivity to Salbutamol, Ipratropium Bromide, atropine or its derivatives, or any component of the formulation
• •Patients with hypertrophic obstructive cardiomyopathy or tachyarrhythmia
• •Acute severe asthma where a rapid response is critical (use single-agent bronchodilator first)

Store below 30°C. Protect from light and moisture. Do not freeze. Keep out of reach of children. Use immediately after opening the protective pouch.

Symptoms of overdose may include tachycardia, palpitations, tremor, hypertension, dry mouth, blurred vision, and urinary retention. Treatment is symptomatic and supportive, discontinuing the drug and monitoring vital signs. Electrolyte monitoring, especially potassium, is advised.

Pregnancy Category C (Salbutamol) and B (Ipratropium Bromide). Use only if the potential benefit justifies the potential risk to the fetus. Both are excreted in breast milk in small amounts; caution should be exercised when administered to a nursing mother.